头孢哌酮/舒巴坦治疗耐药菌与二重感染患者的疗效评价  

To evaluate the effect of cefoperzone/subactam in treating patients infected by drug-resistance bacteria and suffered double infection

作　　者：陈华[1] 胡慧珍[1] 邱海鸯[2] 

机构地区：[1]浙江省磐安县人民医院药剂科,浙江磐安县322300 [2]浙江省磐安县人民医院门诊办,浙江磐安县322300

出　　处：《中华医院感染学杂志》2015年第3期570-571,637,共3页Chinese Journal of Nosocomiology

基　　金：浙江省科技局基金资助项目(CR2009011)

摘　　要：目的研究应用头孢哌酮/舒巴坦治疗耐药菌及二重感染患者进行的临床效果。方法回顾性分析2012年9月-2013年9月应用头孢哌酮/舒巴坦进行治疗的294例耐药菌感染患者及二重感染患者临床资料,采用SPSS 19.0软件进行统计处理。结果共培养出336株病原菌,革兰阴性菌267株占79.46%,革兰阳性菌69株占20.54%;革兰阴性菌对头孢哌酮/舒巴坦敏感率达79.78%;革兰阳性菌对头孢哌酮/舒巴坦敏感率达82.61%;127例二重感染患者培养出病原菌201株,均为革兰阴性菌,其对头孢哌酮/舒巴坦敏感率达80.10%。结论应用头孢哌酮/舒巴坦对耐药菌及二重感染患者进行治疗,效果显著。OBJECTIVE To study the clinical effect of cefoperazone and sulbactam in treating drug-resistance bacteria and patients infected doubly. METHODS The clinical data of 294 cases of patients with drug-resistance bacterial infection and double infection treated with eefoperazone and sulbactam from Sep. 2012 to Sep. 2013 were analyzed retrospectively. SPSS 19.0 software was adopted for statistic analysis. RESULTS A total of 336 strains of pathogenic bacteria were cultured, among them, 267 were gram-negative bacteria, accounting for 79.46%; 69 were gram-positive strains, holding 20. 54%. The sensitive rate of gram-negative bacteria to cefoperazone and sulbactam was 79.78%. But it was 82.61% in gram-positive bacteria. Totally 201 strains of pathogenic bacteria were cultured form the 127 cases of double infection patients. And they, with 80. 10% of sensitive rate to cefoperazone and sulbactam, were all gram-negative bacteria. CONCLUSIOIN The curative effect is remarkable when using cefoperazone and sulbactam to treat patients infected by drug-resistance bacteria and infected doubly.

关 键 词：二重感染 耐药菌感染 药敏试验 抗菌药物 头孢哌酮/舒巴坦 

分 类 号：R978.1[医药卫生—药品]